Azitra (NYSE: AZTR) Gains 87% on June 16 Launch of Filaggrin Protein and Peptide Program for Cosmetic and Cosmeceutical Markets
Azitra, Inc. (NYSE American: AZTR), a clinical-stage precision-dermatology biotech, announced June 16 a strategic launch into the cosmetic and cosmeceutical markets with a new protein and peptide program built on proprietary filaggrin technologies and the company's microbial genetic-engineering platform. Cofounder and COO Travis Whitfill, Ph.D., MPH will present pipeline updates at the BIO International Convention in San Diego on June 23, 2026 at 4:45 PM PT. The stock gained 87% the same day on roughly 251x average trading volume, closing at $0.35. Filaggrin is a structural protein critical for skin-barrier function and a target of growing interest in barrier-repair cosmeceuticals.